Q Bio funding, valuation and investors

Overview

Q Bio is a quantitative medicine company offering comprehensive preventive-health assessments combining full-body MRI, blood biomarkers, and proprietary Tensor Field Mapping technology. Co-founded by Stanford geneticist Michael Snyder and CEO Jeff Kaditz, Q Bio aims to detect disease earlier by tracking physiological changes over time rather than relying on single-point lab tests. The company operates clinical sites and has developed the Mark I full-body MRI scanner for high-throughput screening. Q Bio raised a $40M Series B led by Andreessen Horowitz in 2020, with Khosla Ventures and Founders Fund on the cap table, and a $27M strategic round in 2024 for Mark I manufacturing. It competes in the executive-health and whole-body-scanning space alongside Prenuvo and Ezra, with a stronger emphasis on longitudinal data and Stanford-linked research.

Why Q Bio is interesting

Stanford's Mike Snyder co-founded Q Bio to turn whole-body scanning plus Tensor Field Mapping into a repeatable clinical workflow — not a one-off executive physical.

Product & use cases

Q Bio runs clinical preventive-health programs combining whole-body MRI, blood panels, and Tensor Field Mapping to build longitudinal health profiles. The Mark I scanner supports scalable full-body imaging for early disease detection.

• Executive and preventive whole-body health screening
• Longitudinal biomarker tracking for early disease detection
• Clinical research on quantitative medicine and imaging biomarkers

Key facts

• Co-founded by Stanford geneticist Michael Snyder and CEO Jeff Kaditz
• Series B (2020): $40M led by a16z; Khosla Ventures and Founders Fund participated (Business Wire)
• Strategic round (2024): $27M for Mark I full-body MRI scanner manufacturing (STAT)
• Proprietary Tensor Field Mapping technology for longitudinal health tracking

Funding history (newest first)

Investors in our directory

Funds linked from Q Bio's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Stanford-linked scientific leadership (Mike Snyder) and proprietary Tensor Field Mapping differentiate Q Bio from pure imaging clinics. Longitudinal tracking across visits is the core product thesis, not one-time scans.

Whole-body MRI screening exploded post-COVID with Prenuvo and Ezra raising significant capital. Q Bio's bet is quantitative, longitudinal medicine — tracking change over time with Tensor Field Mapping — rather than selling one-off scans. Regulatory scrutiny of elective MRI and insurance reimbursement remain industry-wide risks. Q Bio's Mark I scanner investment signals vertical integration to control cost and throughput.

• Prenuvo direct

  Whole-body MRI screening with broad consumer marketing; less emphasis on longitudinal quantitative modeling.

• Ezra direct

  AI-assisted MRI screening focused on cancer detection; narrower scope than Q Bio's full quantitative platform.

• Function Health adjacent

  Lab-based biomarker panels without full-body MRI; competes on preventive testing budget.

Notable stories

• Michael Snyder, director of Stanford's Center for Genomics and Personalized Medicine, co-founded Q Bio to apply quantitative biology methods he pioneered in research to clinical preventive care.
• Q Bio developed the Mark I full-body MRI scanner to reduce scan costs and increase throughput for population-scale preventive screening (STAT, 2024).

Industries

Related funding articles

Venture Capital Tracker pieces that cover Q Bio's financing or category context.

• a16z Portfolio Companies on Fire in 2026: AI, American Dynamism & More